Major Investment Alert: Zivo Bioscience Sees Significant Shareholder Action
Mark E. Strome has invested $249,996 in Zivo Bioscience by acquiring 20,259 shares. However, Spark's AI Analyst rates ZIVO as an Underperform due to significant financial challenges, including negative equity and cash flow issues. The company requires urgent financial restructuring for sustainability, with a year-to-date price performance of -41.73% and a current market cap of $47.75M.
Significant shareholder Mark E. Strome has made a notable investment in Zivo Bioscience by purchasing 20,259 shares, valued at $249,996.
Spark’s Take on ZIVO Stock
According to Spark, TipRanks’ AI Analyst, ZIVO is a Underperform.
Zivo Bioscience faces significant financial challenges, including negative equity and cash flow issues, which are the primary factors in its low score. Despite some technical indicators showing neutrality, the company’s negative valuation metrics further impact the score. Urgent financial restructuring is necessary for sustainability.
To see Spark’s full report on ZIVO stock, click here.
More about Zivo Bioscience
YTD Price Performance: -41.73%
Average Trading Volume: 1,252
Technical Sentiment Signal: Sell
Current Market Cap: $47.75M
